56.96 0.00 (0.00%)
After hours: 4:33PM EST
|Bid||54.55 x 800|
|Ask||56.97 x 1000|
|Day's Range||56.74 - 58.00|
|52 Week Range||48.25 - 79.55|
|Beta (3Y Monthly)||1.66|
|PE Ratio (TTM)||16.45|
|Earnings Date||Feb 11, 2019 - Feb 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.91|
NEW YORK, Jan. 22, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
UnitedHealth UNH shares jumped 1 percent in premarket trading Tuesday after it reported fourth-quarter earnings that beat Wall Street's expectations, helped by growth in its services business. Revenue from Optum, which includes the company's pharmacy benefits management business, grew 13 percent to $27.56 billion in the fourth quarter, while revenue from its mainstay insurance business grew 11.1 percent to $46.23 billion. UnitedHealth reaffirmed its 2019 forecast for earnings between $14.40 and $14.70 per share.
In 1999 Kent Thiry was appointed CEO of DaVita Inc. (NYSE:DVA). First, this article will compare CEO compensation with compensation at other large companies. Next, we'll consider growth that the Read More...
Of the ten analysts covering DaVita (DVA), five have given it “buy” or higher ratings, four have given it “holds,” and one has given it a “sell.”
In the third quarter, DaVita’s (DVA) patient care and other costs rose YoY (year-over-year) to $2.06 billion from $1.95 billion. Its gross margin expanded YoY to 27.52% from 25.41%. Expected trends
DaVita’s (DVA) two major business divisions are Kidney Care (DaVita Kidney Care) and DMG (DaVita Medical Group). The Kidney Care division includes its US dialysis and associated lab services, ancillary services, and strategic initiatives such as pharmacy services, disease management, vascular access services, and clinical research programs.
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
DaVita's DVA narrow economic moat is due to the company's dominant and essential position in the U.S. dialysis market, accounting for over one third of all dialysis facilities and patient treatments. DaVita provides lifesaving healthcare services to chronically ill patients in a low-cost, outpatient setting. Because the alternative to outpatient dialysis is higher-cost, less-efficient, and more-burdensome acute therapy, we see little likelihood of DaVita faltering due to regulatory disruption in the long term.
DaVita (DVA) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
NEW YORK, NY / ACCESSWIRE / November 28, 2018 / U.S. markets closed up on Tuesday as gains in defensive stocks helped counteract trade related concerns between U.S. and China. The Dow Jones Industrial ...
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how DaVita Inc’s (NYSE:DVA) P/E Read More...
DaVita was set to give back gains at Wall Street's open Thursday after the dialysis provider reported third-quarter earnings and revenue that missed analysts' expectations.
DaVita shares slid in premarket trading Thursday, threatening to erase much of the previous day's gains. DaVita DVA shares plunged more than 9 percent Thursday, threatening to erase all of the dialysis provider's gains the day before. Investors sold off DaVita after the Denver-based company reported late Wednesday third-quarter earnings of 56 cents per share on revenue of $2.85 billion, missing Wall Street projections on both.
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -37.08% and -2.47%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Nasdaq and S&P 500 led an early rally fueled by election results and earnings news, as Caterpillar and United Health drove the Dow.
Democratic control of the House likely means that Obamacare is safe -- a positive for hospitals and other companies.
It’s human nature to shy away from uncertainty, so with the midterm elections behind us, stocks are gaining ground again.
DaVita shares soared Wednesday after California voters rejected a ballot measure that would have capped the amount of money dialysis providers in the state can earn on certain patients. DaVita operates half of all the chronic dialysis clinics in the state, and spent $66.6 million to defeat the measure. DaVita DVA shares soared Wednesday after California voters rejected a ballot measure that would have capped the amount of money dialysis providers in the state can earn on certain patients.
DaVita shelled out $66.6 million of the more than $110 million spent by the industry lobbying against Proposition 8, which was defeated by California voters on Tuesday.